SCOPUS 정보 검색 플랫폼

Volumn 35, Issue 1, 2002, Pages 81-89

Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer

(4) Rubio Terrés, Carlos a Luis Tisaire, Jose a Kobina, Svetlana b Moyano, Alfredo c

a Aventis Pharma (Spain)

b SANOFI (France)

c HOSPITAL RAMÓN Y CAJAL (Spain)

Author keywords

Carboplatin; Cisplatin; Cost analysis; Docetaxel; Non small cell lung carcinoma; Paclitaxel

Indexed keywords

AMIKACIN; CARBOPLATIN; CEFOTAXIME; CEFTAZIDIME; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DIPHENHYDRAMINE; DOCETAXEL; LOPERAMIDE; METHYLPHENIDATE; NORTRIPTYLINE; ONDANSETRON; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST MINIMIZATION ANALYSIS; DOSE RESPONSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; NEOPLASM STAGING; PACLITAXEL; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TAXOIDS;

EID: 0036135850 PISSN: 01695002 EISSN: None Source Type: Journal
DOI: 10.1016/S0169-5002(01)00280-X Document Type: Article

Times cited : (25)

References (36)

1
- 2042534660
- Centro Nacional de Epidemiología, January 2001
- (1997) Mortalidad por cáncer en España

2
- 0000185168
- Mortalidad en España 1995. Mortalidad general y principales causas de muerte y de años potenciales de vida perdidos (I)
- (1998) Bol Epidemiol Sem , vol.6 , pp. 105-116
- Martinez de Aragón, M.V.¹ Llácer, A.²

3
- 0000694849
- Mortalidad en España 1995. Mortalidad general y principales causas de muerte por grupos de edad (II)
- (1998) Bol Epidemiol Sem , vol.6 , pp. 117-128
- Martinez de Aragón, M.V.¹ Llácer, A.²

4
- 2042439046
- 16 May
- (1997) Clinical Practice Guidelines for the Treatment of Unresectable Non-Small-Cell Lung Cancer

5
- 0028843552
- Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
- (1995) Br Med J , vol.311 , pp. 899-909

6
- 0000170214
- A meta-analysis using individual patient data from randomised clinical trials (RCTS) of chemotherapy (CT) in non-small cell lung cancer (NSCLC): (2) survival in the locally advanced (LA) setting
- (1994) Proc Am Soc Clin Oncol , vol.13 , pp. 334
- Pignon, J.P.¹ Stewart, L.A.² Souhami, R.L.³

7
- 0028031433
- Chemotherapy vs supportive care in advanced non-small cell lung cancer: Results of a meta-analysis of the literature
- (1994) Chest , vol.106 , pp. 861-865
- Marino, P.¹ Pampallona, S.² Preatoni, A.³

8
- 2042475358
- October
- (1999) PDQ Treatment Health Professionals: Non-Small Cell Lung Cancer

9
- 0031665741
- Pharmacoeconomic models in disease management. A guide for the novice or the perplexed
- (1998) Dis Manage Health Outcomes Res , vol.4 , pp. 119-134
- Milne, R.J.¹

10
- 0002515933
- A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
- abstract
- (2000) Proc Am Soc Clin Oncol , vol.19 , pp. 2
- Schiller, J.H.¹ Harrington, D.² Sandler, A.³ Belani, C.⁴ Langer, C.⁵ Krook, J.⁶

11
- 2042476010
- A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
- 20-23 May 200, New Orleans, LA (40 screens)
- Proceedings of the 36th American Society of Medical Oncology Annual Meeting
- Schiller, J.H.¹

12
- 0012303732
- Madrid: Medimedia-Medicom, SA
- (2000) Vademecum Internacional

13
- 0003915209
- Madrid: Consejo General de Colegios de Farmacéuticos
- (2000) Catalogo de Especialidades Farmacéuticas 2000

14
- 0031796399
- Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small cell lung cancer
- (1998) Ann Oncol , vol.9 , pp. 1079-1084
- Sekine, I.¹ Kubota, K.² Nishiwaki, Y.³ Sasaki, Y.⁴ Tamura, T.⁵ Saijo, N.⁶

15
- 0019365237
- Reporting results of cancer treatment
- (1981) Cancer , vol.47 , pp. 207-214
- Miller, A.B.¹ Hoogstraten, B.² Staquet, M.³ Winkler, A.⁴

16
- 0029096271
- Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation
- (1995) PharmacoEconomics , vol.8 , pp. 245-252
- Rovira, J.¹ Antoñanzas, F.²

17
- 0003473937
- Ottawa: Canadian Coordinating Office for the Health Technology Assessment (CCOHTA)
- (1996) A Guidance Document for the Costing Process, Version 1.0
- Baladi, J.F.¹

18
- 0004112867
- Indianapolis: Butler University College of Pharmacy and Health Sciences
- (1998) Beyond Acquisition: Using Cost-Minimization Analysis to Determine and Compare the Cost of Equally Effective Medications
- Baskin, L.E.¹

19
- 0029808877
- Economic value of gemcitabine in non-small cell lung cancer
- (1996) Sem Oncol , vol.23 , Issue.SUPPL. 10 , pp. 90-98
- Copley-Merriman, C.¹ Martin, C.² Johnson, N.³ Sacristán, J.A.⁴ Drings, P.A.⁵ Bosanquet, N.⁶

20
- 0031712703
- Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer
- (1998) Med Oncol , vol.15 , pp. 129-136
- Tennval, G.R.¹ Fernberg, J.O.²

21
- 0029844206
- The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages IIIB and IV non-small cell lung cancer: An Italian perspective
- (1996) Monaldi Arch Chest Dis , vol.51 , pp. 279-288
- Palmer, A.J.¹ Brandt, A.²

22
- 0032587583
- Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
- (1999) Br J Cancer , vol.80 , pp. 815-820
- Earle, C.C.¹ Evans, W.K.²

23
- 0003907429
- Hospitales INSALUD. Madrid: Instituto Nacional de la Salud
- (1995) Proyecto Coste por Proceso

24
- 0002552916
- Consenso sobre el diseño de un modelo farmacoeconómico útil para la valoración de antibióticos parenterales de uso hospìtalarto
- (1997) Rev Esp Farmacoeconomía , vol.3 , pp. 35-49
- Azanza, J.R.¹ Cameán, M.² Cercós, A.C.³ Domínguez-Gil, A.⁴ Escrivá, J.⁵ Gobernado, M.⁶

25
- 0003811135
- Soikos Barcelona
- (2000) Base de Datos de Costes Sanitarios. Version 1.1c
- Gisbert, R.¹ Brosa, M.²

26
- 0029012359
- Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors
- (1995) J Natl Cancer Inst , vol.87 , pp. 803-808
- Mayordomo, J.I.¹ Rivera, F.² Díaz-Puente, M.T.³ Lianes, P.⁴ Colomer, R.⁵ Lopez-Brea, M.⁶

27
- 0033740834
- Evaluación farmacoeconómica del docetaxel versus paclitaxel en el tratamiento del cáncer de mama metastásico
- (2000) Farm Hosp , vol.24 , pp. 226-240
- Ferriols, F.¹ Ferriols, R.² Magraner, J.³

28
- 2042437018
- Indicaciones y utilización clinica de la sangre y hemoderivados
- Madrid: Ministerio de Sanidad y Consumo
- (1986) Hospital General La Paz: Manual de urgencias médicas
- Arnalich, F.¹

29
- 0031712703
- Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer
- (1998) Med Oncol , vol.15 , pp. 129-136
- Ragnarson, G.¹ Fernberg, J.O.²

30
- 0004055931
- Barcelona 2000: Masson
- (2000) Guía de terapéutica antimicrobiana
- Mensa, J.¹ Gatell, J.M.² Jiménez de Anta, M.T.³ Prats, G.⁴ Corachan, M.⁵ Escofet, M.C.⁶ Martínez, J.A.⁷ Zamora, L.⁸

31
- 0029620383
- Economic analysis of toxicity secondary to anthracycline-based breast cancer chemotherapy
- (1995) Eur J Cancer , vol.31 , pp. 2174-2180
- Dranitsaris, G.¹ Tran, T.M.²

32
- 26744461135
- Nausea y vómitos

33
- 0003627899
- Madrid: McGraw-Hill/Interamericana
- (1998) Harrison Principios de medicina interna. Compendio
- Fauci, A.S.¹ Braunwald, E.² Isselbacher, K.J.³ Wilson, J.D.⁴ Martin, J.B.⁵ Kasper, D.L.⁶ Hauser, S.L.⁷ Longo, D.L.⁸

34
- 2042514274
- (1994) Diagnosis and management of sensory neuropathy in HIV infection
- Dal Pan, G.J.¹ McArthur, J.C.²

35
- 0031740745
- Pharmacoeconomic analysis in new drug development: A pragmatic approach to efficiency studies
- (1998) Clin Res Reg Affairs , vol.15 , pp. 209-223
- Rubio Terrés, C.¹

36
- 2042474709
- Comparative cost efficiency of platinum based combination chemotherapy regimens for advanced non-small cell lung cancer (NSCLC)
- 12-15 May, San Francisco, CA
- (2001) Proceedings of the 37th American Society of Medical Oncology Annual Meeting
- Reaume, M.N.¹ Coyle, D.² Quinn, C.³ Hopkins, S.⁴ Simpson, R.⁵ Evans, W.K.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.